These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8660948

  • 1. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines.
    Johnson SW, Shen D, Pastan I, Gottesman MM, Hamilton TC.
    Exp Cell Res; 1996 Jul 10; 226(1):133-9. PubMed ID: 8660948
    [Abstract] [Full Text] [Related]

  • 2. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC.
    Biochem Pharmacol; 1994 Feb 11; 47(4):689-97. PubMed ID: 8129746
    [Abstract] [Full Text] [Related]

  • 3. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC.
    Cancer Res; 1997 Mar 01; 57(5):850-6. PubMed ID: 9041185
    [Abstract] [Full Text] [Related]

  • 4. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT, Shellard SA, Hosking LK, Fichtinger-Schepman AM, Bedford P.
    Int J Radiat Oncol Biol Phys; 1990 Jul 01; 19(1):75-83. PubMed ID: 2380098
    [Abstract] [Full Text] [Related]

  • 5. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Shellard SA, Hosking LK, Hill BT.
    Biochem Pharmacol; 1994 Mar 02; 47(5):775-9. PubMed ID: 8135853
    [Abstract] [Full Text] [Related]

  • 6. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC.
    Cancer Res; 1994 Nov 15; 54(22):5911-6. PubMed ID: 7954422
    [Abstract] [Full Text] [Related]

  • 7. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR.
    Br J Cancer; 1998 Nov 15; 77(3):366-73. PubMed ID: 9472630
    [Abstract] [Full Text] [Related]

  • 8. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR.
    Br J Cancer; 1992 Dec 15; 66(6):1109-15. PubMed ID: 1457352
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan 15; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 10. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR.
    Cancer Res; 1992 Apr 01; 52(7):1710-6. PubMed ID: 1312897
    [Abstract] [Full Text] [Related]

  • 11. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 01; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 12. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    Materna V, Liedert B, Thomale J, Lage H.
    Int J Cancer; 2005 Jun 20; 115(3):393-402. PubMed ID: 15688364
    [Abstract] [Full Text] [Related]

  • 13. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.
    Oldenburg J, Begg AC, van Vugt MJ, Ruevekamp M, Schornagel JH, Pinedo HM, Los G.
    Cancer Res; 1994 Jan 15; 54(2):487-93. PubMed ID: 8275486
    [Abstract] [Full Text] [Related]

  • 14. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA, Hosking LK, Hill BT.
    Cancer Res; 1991 Sep 01; 51(17):4557-64. PubMed ID: 1873800
    [Abstract] [Full Text] [Related]

  • 15. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 16. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 17. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 15; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 18. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
    Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA, Zunino F.
    Biochem Pharmacol; 1998 Apr 15; 55(8):1247-54. PubMed ID: 9719480
    [Abstract] [Full Text] [Related]

  • 19. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994 Apr 15; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 20. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L.
    Cancer Chemother Pharmacol; 2001 Nov 15; 48(5):398-406. PubMed ID: 11761458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.